Reviews| Volume 18, ISSUE 9, P1063-1076, September 2016

Download started.


Managing particulates in cell therapy: Guidance for best practice


      The intent of this article is to provide guidance and recommendations to cell therapy product sponsors (including developers and manufacturers) and their suppliers in the cell therapy industry regarding particulate source, testing, monitoring and methods for control. This information is intended to help all parties characterize the processes that generate particulates, understand product impact and provide recommendations to control particulates generated during manufacturing of cell therapy products.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Alliance for Regenerative Medicine
        Alliance for regenerative medicine quarterly data report Q3.
        (accessed 12.15)
        • Negrin R.S.
        Introduction to the review series on “Advances in hematopoietic cell transplantation”.
        Blood. 2014; 124: 307
        • Das T.K.
        Protein particulate detection issue in biotherapeutic development—current status.
        AAPS PharmSciTech. 2012; 13: 732-746
        • Langille S.E.
        Particulate matter in injectable drug products.
        PDA J Pharm Sci Technol. 2013; 67: 186-200
        • Davis K.
        • Evrard P.
        • Isberg E.
        • Jenness E.
        • Johnson M.
        • Kollar C.
        • et al.
        Recommendations for testing, evaluation, and control of particulates from single-use process equipment.
        Bio-Process Systems Alliance, Washington, DC2014
        • ISPE
        ISPE good practice guide: assessing the particulate containments performance of pharmaceutical equipment.
        International Society for Pharmaceutical Engineering, Tampa, FL2012
        • Clarke D.
        • Harati D.
        • Martin J.
        • Rowley J.
        • Keller J.
        • McCaman M.
        • et al.
        Managing particulates in cellular therapy.
        Cytotherapy. 2012; 14: 1032-1040
        • Cunha B.
        • Aguiar T.
        • Silva M.
        • Silva R.
        • Sousa M.
        • Pineda E.
        • et al.
        Exploring continuous and integrated strategies for the up- and downstream processing of human mesenchymal stem cells.
        J Biotechnol. 2015; 10: 97-108
        • Bukofzer S.
        • Ayres J.
        • Chavez A.
        • Devera M.
        • Miller J.
        • Ross D.
        • et al.
        Industry perspective on the medical risk of visible particles in injectable drug products.
        PDA J Pharm Sci Technol. 2015; 69: 123-139
        • Fischer U.M.
        • Harting M.T.
        • Jimenez F.
        • Monzon-Pasadas W.O.
        • Xue H.
        • Savitz S.I.
        • et al.
        Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect.
        Stem Cells Dev. 2009; 18: 683-691
        • Kringsholm B.
        • Christofferson P.
        The nature and the occurrence of birefringent material in different organs in fatal drug addiction.
        Forensic Sci Int. 1987; 34: 53-62
        • Coughlin P.A.
        • Mayor A.D.
        Arterial consequences of recreational drug use.
        Eur J Vasc Endovasc Surg. 2006; 32: 389-396
        • Reedy J.S.
        • Kuhlman J.E.
        • Voytovich M.
        Microvascular pulmonary emboli secondary to precipitated crystals in a patient receiving total parenteral nutrition: a case report and description of the high-resolution CT findings.
        Chest. 1999; 115: 892-895
        • Pesko L.J.
        Physiological consequences of injected particulates.
        in: Knapp J.Z. Barber T.A. Lieberman A. Liquid- and surface-borne particle measurement handbook. Marcel Dekker, New York1996: 661-686
        • Barber T.A.
        Control of particulate matter contamination in healthcare manufacturing.
        Interpharm Press, Denver, CO2000
        • Jack T.
        • Brent B.E.
        • Boehne M.
        • Muller M.
        • Sewald K.
        • Braun A.
        • et al.
        Analysis of particulate contamination of infusion solutions in a pediatric intensive care unit.
        Intensive Care Med. 2010; 36: 707-711
        • Tawde S.A.
        Particulate matter in injectables: main cause for recalls.
        J Pharmacovigil. 2014; 3: 1-2
        • Muylle L.
        The role of cytokines in blood transfusion reactions.
        Blood Rev. 1995; 9: 77-83
        • Jaganathan H.
        • Godin B.
        Biocompatibility assessment of Si-based nano- and micro-particles.
        Adv Drug Deliv Rev. 2012; 64: 1800-1819
        • Moerke C.
        • Mueller P.
        • Nebe B.
        Attempted caveolae-mediated phagocytosis of surface-fixed micro-pillars by human osteoblasts.
        Biomaterials. 2016; 76: 102-114
        • Oren R.
        • Farnham A.E.
        • Saito K.
        • Milofsky E.
        • Karnovsky M.L.
        Metabolic patterns in three types of phagocytizing cells.
        J Cell Biol. 1963; 17: 487-501
        • Laquerriere P.
        • Grandjean-Laquerriere A.
        • Guenounou M.
        • Laurent-Maquin D.
        • Frayssinet P.
        • Nardin M.
        Correlation between sintering temperature of hydroxyapatite particles and the production of inflammatory cytokines by human monocytes.
        Colloids Surf B Biointerfaces. 2003; 30: 207-213
        • Foged C.
        • Brodin B.
        • Frokjaer S.
        • Sundblad A.
        Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model.
        Int J Pharm. 2005; 298: 315-322
        • USP <1>
        (U.S. Pharmacopeia National Formulary)2009
        • EP 2.9.20
        Particulate Contamination: Visible Particles.
        (European Pharmacopeia)2008
        • JP 6.06
        Foreign Insoluble Matter Test for Injections.
        (Japanese Pharmacopoeia)2013
        • USP <788>
        Particulate Matter for Injections.
        (U.S. Pharmacopeia National Formulary)2012
        • ASTM F24-09 (2015)
        Standard test method for measuring and counting particulate contamination on surfaces.
        ASTM International, West Conshohocken, PA2015
        • Thornton R.M.
        Pharmaceutical sterile cleanrooms.
        Pharm Tech. 1990; 14: 44-48
        • Austin P.R.
        The encyclopedia of cleanrooms, bio-cleanrooms and aseptic areas.
        3rd ed. Acorn Industries, Livonia, MI2000
      1. Mollah H. Baseman H. Long M. Risk management applications in pharmaceutical and biopharmaceutical manufacturing. John Wiley & Sons, Inc., Hoboken, NJ2013